TB-500 and Sermorelin Stack: When to Pick One, the Other, or Both

What TB-500 and Sermorelin Actually Do (and Why Women Use Them Together)

TB-500 and sermorelin work through completely different pathways, which is exactly why some clinicians reach for both. TB-500 is a synthetic version of the active region of thymosin beta-4, a 43-amino-acid protein found in most human cells. Research published in the Annals of the New York Academy of Sciences showed thymosin beta-4 promotes actin polymerization, cell migration, and angiogenesis in injured tissue, making it useful for accelerating repair after musculoskeletal injuries, surgeries, or chronic inflammation. Sermorelin, by contrast, is a 29-amino-acid analogue of growth-hormone-releasing hormone (GHRH) that binds to the GHRH receptor on your pituitary gland and triggers a natural GH pulse.

The reason women stack them comes down to two converging biological problems. Tissue repair slows with age and hormonal shifts. GH secretion also declines, dropping roughly 14% per decade after age 30. Stacking TB-500 with sermorelin attempts to address both simultaneously: repair the tissue faster while restoring the anabolic hormonal environment that supports that repair.

How TB-500 Works in Women

Thymosin beta-4 and its active fragment have been studied most extensively in wound healing and cardiac repair. A 2010 paper in Circulation demonstrated that thymosin beta-4 activated epicardial progenitor cells and improved cardiac function in a mouse model of myocardial infarction. In women specifically, no published RCT exists, but the mechanistic data suggests TB-500 may be particularly relevant after ligament and tendon injuries, which women sustain at higher rates than men due to differences in collagen structure, laxity influenced by estrogen, and biomechanical loading patterns.

How Sermorelin Works in Women

Sermorelin binds GHRH receptors on the anterior pituitary and stimulates the release of endogenous GH, which in turn drives hepatic production of IGF-1. This is distinct from exogenous HGH injection: sermorelin works with your pituitary's existing feedback loops, so it does not fully suppress natural GH secretion. The FDA approved sermorelin acetate (Geref) for GH deficiency in children before the approval was withdrawn for commercial reasons unrelated to safety. Adult off-label use is now driven almost entirely by compounded formulations.

Women's GH secretion is not the same as men's. Pre-menopausal women have higher GH pulse frequency and amplitude than age-matched men, largely because estrogen amplifies GHRH signaling. A study in the Journal of Clinical Endocrinology and Metabolism found that estrogen increases GH secretory burst mass in women, meaning that as estrogen falls in perimenopause and post-menopause, GH output drops faster than in men of the same age. That estrogen-GH connection is clinically important: a post-menopausal woman who is not on estrogen therapy may respond differently to sermorelin than a pre-menopausal woman or one on hormone therapy.

The Evidence (and Its Serious Limits)

Be direct about this: neither TB-500 nor sermorelin has been studied in a randomized controlled trial specifically in women for the indications most women are using them for, including body composition, injury recovery, sleep, and perimenopausal symptoms.

What Animal Studies Show

A murine study published in PLOS ONE in 2014 showed thymosin beta-4 significantly reduced skeletal muscle fibrosis and improved regeneration after acute injury. Rodent models consistently show accelerated wound closure and reduced inflammation with thymosin beta-4. For sermorelin, a rat model published in Rejuvenation Research demonstrated improved GH/IGF-1 signaling and reduced visceral fat accumulation with GHRH analogue therapy in aging animals.

What Human Data Exists

For TB-500 as a standalone, published human trial data is essentially absent. Practitioners and patients report outcomes in online forums and in case series shared at peptide-focused conferences, none of which constitute controlled evidence.

For sermorelin in adults, the best available data comes from studies of GHRH analogues in GH-deficient adults and, importantly, from research on tesamorelin (a stabilized GHRH analogue). A placebo-controlled trial published in the New England Journal of Medicine in 2010 showed tesamorelin reduced visceral adiposity by 15% in HIV-associated lipodystrophy patients. That trial included women, though the primary population was men. The biology is likely transferable to sermorelin because the mechanism is identical, but it is extrapolation, not direct evidence.

WomanRx Evidence Framework for This Stack:

| Claim | Evidence Source | Confidence | |---|---|---| | TB-500 accelerates tissue repair | Animal studies, mechanistic data | Low-Moderate (extrapolated) | | Sermorelin raises IGF-1 in adults | Adult human GHRH studies | Moderate (not women-specific) | | Stack produces additive benefit | Practitioner case series only | Very Low | | Stack is safe long-term in women | No data | Unknown |

When to Pick One Over the Stack

This is the clinical decision most women actually want answered. Three questions help narrow it down.

Scenario 1: You Have an Acute Injury or Slow Healing

TB-500 alone is the more targeted choice. If you have a tendon injury, a surgical wound that is healing slowly, or chronic soft-tissue inflammation without a metabolic or hormonal component, adding sermorelin does not obviously change the tissue-repair pathway. The additional cost and injection burden may not be justified.

Women healing from ligament injuries (ACL reconstruction is a common example) may have a plausible rationale for TB-500 based on the tissue-repair mechanism, though no published trial exists in this population.

Scenario 2: Your Primary Goal Is Body Composition and Sleep Quality

Sermorelin alone is reasonable first. Restoring natural GH pulsatility may improve lean mass, reduce truncal fat, deepen slow-wave sleep, and improve skin quality. These are the outcomes most commonly reported with GHRH-based peptides. If you try sermorelin for 3-4 months and hit a plateau, or if you also have a significant inflammatory or injury burden, adding TB-500 becomes more defensible.

Scenario 3: You Are Perimenopausal or Post-Menopausal with Multiple Complaints

The stack may make the most sense here. The combination of falling estrogen, declining GH, slower healing, increased visceral fat, disrupted sleep, and joint aches represents overlapping problems. Addressing both the GH axis (sermorelin) and the local tissue-repair environment (TB-500) is mechanistically logical, though "mechanistically logical" is not the same as "proven in a trial."

A 2019 position statement from The Menopause Society (NAMS) notes that the hormonal milieu of menopause creates compounding changes in body composition, sleep architecture, and tissue integrity, all of which drive interest in adjunct therapies. Neither TB-500 nor sermorelin is mentioned in that statement because neither is approved, but the biological rationale maps onto well-documented menopausal physiology.

Dosing Protocols Used in Practice

These protocols reflect compounded-peptide clinical practice and practitioner-reported use. They are not FDA-approved regimens. Doses should be confirmed with a prescribing clinician who has reviewed your full hormonal and metabolic panel.

Sermorelin Protocol

• Standard dose: 200-500 mcg subcutaneously, injected at bedtime, 3-5 nights per week
• Rationale for bedtime dosing: GH is secreted in a circadian pattern, with the largest pulse occurring in early slow-wave sleep. Research in the Journal of Clinical Endocrinology and Metabolism confirmed that GHRH-stimulated GH release is amplified when given in synchrony with the sleep-onset GH pulse.
• Monitoring: IGF-1 levels at baseline and at 8-12 weeks. Target IGF-1 within the age-adjusted reference range, not maximized.
• Cycle length: Many practitioners use 5 days on, 2 days off to preserve receptor sensitivity. Cycles of 3-6 months followed by a break are commonly used.

TB-500 Protocol

• Loading phase: 2-2.4 mg subcutaneously twice weekly for 4-6 weeks
• Maintenance: 2 mg subcutaneously once monthly, or as needed around injury events
• Reconstitution: Lyophilized peptide is reconstituted in bacteriostatic water. Most compounded vials are 5 mg.
• Injection site: Subcutaneous, abdomen or thigh preferred. Rotating sites reduces local irritation.

Stack Timing

When using both, most practitioners separate the injections. Sermorelin at bedtime daily (or 5 nights per week) and TB-500 twice weekly in the morning is the most commonly reported schedule. No pharmacokinetic study has tested whether co-administration changes bioavailability of either peptide.

Pregnancy, Lactation, and Contraception: Required Reading

Both TB-500 and sermorelin are contraindicated in pregnancy and should not be used while breastfeeding. This section is not optional to read if there is any possibility you could become pregnant.

Pregnancy

There are no human safety data for either peptide in pregnancy. TB-500 promotes cell migration and angiogenesis, including in embryonic tissue, where uncontrolled cell migration is precisely what you do not want. Animal developmental toxicity studies have not been completed for the synthetic fragment used in compounded formulations. For sermorelin, GH axis activation in the first trimester carries theoretical risk given the role of IGF-1 in placental development and fetal overgrowth, though again, no human trial data exists. ACOG consistently advises that any unapproved, investigational, or compounded peptide without human pregnancy safety data should be avoided throughout pregnancy.

If you are trying to conceive, you should stop both peptides at least one full menstrual cycle before attempting conception. This allows time for the GH axis to re-equilibrate and removes any speculative embryotoxic risk during implantation.

Lactation

Neither peptide has measured lactation transfer data in humans. Peptides are generally poor candidates for oral absorption in an infant because proteases in the GI tract degrade them rapidly. The theoretical risk from breastmilk transfer is probably low, but "probably low" and "safe" are not the same statement. The LactMed database at the National Library of Medicine does not have entries for TB-500 or sermorelin because no transfer studies exist. Avoid both during lactation.

Contraception Requirement

Women of reproductive age using either peptide should use reliable contraception. Methods that do not interact with peptide therapy include barrier methods (condoms, diaphragm), copper IUD, and hormonal IUDs. Combined oral contraceptives affect GH secretion: research published in Clinical Endocrinology showed that oral estrogen reduces hepatic IGF-1 production and can blunt the IGF-1 response to GHRH stimulation. If you are on oral contraceptives, your sermorelin response may be attenuated compared to someone on a non-oral hormonal method or no hormonal contraception.

Who This Stack Is Right For (and Who Should Avoid It)

More Likely to Benefit

• Women aged 35-60 with documented low-normal IGF-1, persistent difficulty recovering from musculoskeletal injuries, and poor slow-wave sleep not explained by another diagnosis
• Perimenopausal and post-menopausal women who have already optimized estrogen and progesterone therapy and want to address remaining body-composition concerns
• Women with histories consistent with suboptimal GH secretion (childhood short stature, prior cranial radiation, or pituitary pathology confirmed with GH stimulation testing) should have a formal endocrinology evaluation before using any GHRH analogue

More Likely to Be Harmed or to See No Benefit

• Women who are pregnant or breastfeeding (contraindicated, as above)
• Women with active or history of cancer: GH axis activation is potentially oncogenic, and thymosin beta-4 promotes angiogenesis, which tumors exploit. The Endocrine Society's clinical practice guideline on GH deficiency explicitly contraindicates GH therapy in active malignancy, and the same logic applies to GH secretagogues.
• Women with acromegaly or elevated baseline IGF-1
• Women with untreated hypothyroidism: GH secretagogue therapy will not produce meaningful IGF-1 response if thyroid hormone is inadequate, because thyroid hormone is required for GH-stimulated IGF-1 synthesis in the liver
• Women with uncontrolled type 2 diabetes or significant insulin resistance: GH raises fasting glucose and reduces insulin sensitivity acutely, and TB-500 has not been studied in diabetic women

Side Effects Women Report

Side effects reported with sermorelin include transient flushing at the injection site, facial flushing, headache, and daytime fatigue if the bedtime dose is too high. Water retention with mild joint swelling is the most common reason women reduce their sermorelin dose. Carpal tunnel syndrome can occur with excess GH stimulation and typically resolves with dose reduction.

TB-500 side effects reported in compounded-peptide clinical practice include temporary fatigue in the first week of loading, mild headache, and, rarely, a head-rush sensation after injection. No serious adverse events have been reported in published case series, though the total number of reported cases is small.

The most clinically important monitoring point for the stack is IGF-1 level. Running IGF-1 above the upper limit of the age-adjusted normal range increases the risk of fluid retention, insulin resistance, and theoretical cancer risk. A large European cohort study published in The Lancet found that IGF-1 levels in the upper quartile of the normal range were associated with modestly elevated risk of pre-menopausal breast cancer. That association does not prove causation, and it was observed with endogenous IGF-1, not peptide-stimulated IGF-1, but it is a reason to keep IGF-1 within range rather than maximized.

Alternatives to the Stack

If you are not a candidate for the full stack, or if cost is a factor, consider these options.

Sermorelin alone is the lower-cost, lower-complexity starting point for women whose primary issue is GH axis decline with age.

CJC-1295 with ipamorelin is a GHRH plus GHRP combination that many practitioners prefer over sermorelin alone because the half-life of CJC-1295 is longer, allowing less frequent dosing. The mechanism is broadly similar.

BPC-157 is a tissue-repair peptide with a different mechanism from TB-500 and a slightly larger (though still thin) body of animal evidence. Some practitioners use BPC-157 instead of TB-500 for GI-related inflammation and tendon issues.

Optimizing estrogen and progesterone first in perimenopausal and post-menopausal women is the evidence-based foundation. No peptide stack replaces the well-documented benefits of hormone therapy in this population. A 2022 NAMS position statement affirms that for women under 60 or within 10 years of menopause onset, hormone therapy has a favorable benefit-risk ratio for vasomotor symptoms and quality of life.

Monitoring Labs Before and During Use

Before starting either peptide, a prescribing clinician should review:

• IGF-1 (baseline and at 8-12 weeks on sermorelin)
• Fasting glucose and insulin (GH raises insulin resistance acutely)
• TSH and free T4 (hypothyroidism blunts IGF-1 response to sermorelin)
• Estradiol and FSH (hormonal status changes sermorelin response; see above)
• CBC and CMP (general safety baseline)
• Breast cancer screening up to date (mammogram per age-appropriate guidelines before starting GH-axis therapy)

Women on hormone therapy should confirm that their clinician knows about peptide use, as GH axis activation and estrogen interact on multiple levels, including fluid balance and hepatic protein synthesis.